Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Eur J Pharm Biopharm. 2018 Nov;132:19-28. doi: 10.1016/j.ejpb.2018.09.001. Epub 2018 Sep 1.

Time-dependent effects on small intestinal transport by absorption-modifying excipients.

Author information

1
Department of Pharmacy, Uppsala University, Uppsala, Sweden.
2
AstraZeneca R&D, Gothenburg, Sweden.
3
Department of Neuroscience, Division of Physiology, Uppsala University, Uppsala, Sweden.
4
Department of Pharmacy, Uppsala University, Uppsala, Sweden. Electronic address: hans.lennernas@farmaci.uu.se.

Abstract

The relevance of the rat single-pass intestinal perfusion model for investigating in vivo time-dependent effects of absorption-modifying excipients (AMEs) is not fully established. Therefore, the dynamic effect and recovery of the intestinal mucosa was evaluated based on the lumen-to-blood flux (Jabs) of six model compounds, and the blood-to-lumen clearance of 51Cr-EDTA (CLCr), during and after 15- and 60-min mucosal exposure of the AMEs, sodium dodecyl sulfate (SDS) and chitosan, in separate experiments. The contribution of enteric neurons on the effect of SDS and chitosan was also evaluated by luminal coadministration of the nicotinic receptor antagonist, mecamylamine. The increases in Jabs and CLCr (maximum and total) during the perfusion experiments were dependent on exposure time (15 and 60 min), and the concentration of SDS, but not chitosan. The increases in Jabs and CLCr following the 15-min intestinal exposure of both SDS and chitosan were greater than those reported from an in vivo rat intraintestinal bolus model. However, the effect in the bolus model could be predicted from the increase of Jabs at the end of the 15-min exposure period, where a six-fold increase in Jabs was required for a corresponding effect in the in vivo bolus model. This illustrates that a rapid and robust effect of the AME is crucial to increase the in vivo intestinal absorption rate before the yet unabsorbed drug in lumen has been transported distally in the intestine. Further, the recovery of the intestinal mucosa was complete following 15-min exposures of SDS and chitosan, but it only recovered 50% after the 60-min intestinal exposures. Our study also showed that the luminal exposure of AMEs affected the absorptive model drug transport more than the excretion of 51Cr-EDTA, as Jabs for the drugs was more sensitive than CLCr at detecting dynamic mucosal AME effects, such as response rate and recovery. Finally, there appears to be no nicotinergic neural contribution to the absorption-enhancing effect of SDS and chitosan, as luminal administration of 0.1 mM mecamylamine had no effect.

KEYWORDS:

Absorption modifiers; Bioequivalence; Biopharmaceutical Classification System; Epithelial recovery; Intestinal perfusion; Intestinal permeability; Permeation enhancers; Pharmaceutical development

PMID:
30179738
DOI:
10.1016/j.ejpb.2018.09.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center